Long‐Term Safety of a Coordinated Delivery Tablet of Enteric‐Coated Aspirin 325 mg and Immediate‐Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk
ConclusionsLong‐term treatment with PA32540 once daily for up to 12 months in subjects at risk for aspirin‐associated UGI events is not associated with any new or unexpected safety events. Clinical trials. gov identifier: NCT00995410.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Jay L. Goldstein, David J. Whellan, James M. Scheiman, Byron L. Cryer, Glenn M. Eisen, Angel Lanas, John G. Fort Tags: Original Research Article Source Type: research
More News: Acid Reflux | Aspirin | Cardiology | Cardiovascular | Clinical Trials | Dyspepsia | Endoscopy | Eyes | Gastric Ulcer | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Heart | Heart Attack | Omeprazole | Prilosec | Stroke | Study | Upper Endoscopy